TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00603083
Drug: Ropivacaine, Ketorolac and Adrenalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
Study: NCT02757521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Study: NCT01365533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one tablet once daily, orally
Study: NCT02760758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active ingredients
Study: NCT00603083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
Study: NCT00861796
Drug: CYR-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental arm
Study: NCT00861796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00902941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg daily orally for 120 days
Study: NCT00692458
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo; oral, once daily for approximately 60 months
Study: NCT01985646
Drug: oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral probiotic
Study: NCT02907437
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline as an add-on drug (200 mg/day)
Study: NCT02907437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (200 mg/day)
Study: NCT00827736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)
Study: NCT00890890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
Study: NCT02399397
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
Study: NCT02460055
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
Study: NCT02096614
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
Study: NCT01014221
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
Study: NCT00104767
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05642546
Drug: NM8074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases
Study: NCT05642546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Placebo
Study: NCT01127906
Drug: Placebo suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo suspension (matched to PF-04531083 suspension)
Study: NCT01127906
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo tablet (matched to Oxycodone)
Study: NCT02994784
Drug: Propylene Glycol-Free Melphalan Hydrochloride
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Propylene Glycol-Free Melphalan Hydrochloride
Study: NCT00932971
Drug: PEG-IFN alfa-2a, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
Study: NCT00371059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mgs BD
Study: NCT00953914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
Study: NCT00439166
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule, 100 mg, b.i.d., daily for 1 year
Study: NCT00439166
Drug: Placebo matched to doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
Study: NCT03988010
Drug: Placebo (for amantadine sulphate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 cc 0.9% sodium chloride
Study: NCT03354637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution
Study: NCT04340765
Drug: 18F-fluorocholine
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual phase 18F-fluorocholine PET/CT
Study: NCT03072381
Drug: Corticosteroid Control - Group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
Study: NCT01622348
Drug: IMO-3100 at 0.16 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
Study: NCT03865953
Drug: LAT8881
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAT8881 oral capsule
Study: NCT03865953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT01622348
Drug: Saline for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
Study: NCT01622348
Drug: IMO-3100 at 0.32 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
Study: NCT02484560
Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00131963
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00131963
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01047475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6# TID with meal
Study: NCT02772718
Drug: XOMA 358 single dose level A
Approvals — FDA: no, EMA: no, PMDA: no
Description: XOMA 358 single dose level A administered by intravenous infusion
Study: NCT02772718
Drug: XOMA 358 single dose level C
Approvals — FDA: no, EMA: no, PMDA: no
Description: XOMA 358 single dose level C administered by an intravenous infusion
Study: NCT00483028
Drug: donezepil (Aricept)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04071119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants administer the placebo (40 IU) twice a day for 5 - 7 days
Study: NCT01731587
Drug: Cyclophosphamide (CPA)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
Study: NCT04409522
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
Study: NCT04129047
Drug: A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA
Approvals — FDA: no, EMA: no, PMDA: no
Description: a multiple shade universal composite that needs prior shade selection procedure
Study: NCT02556905
Drug: REVLIMID®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
Study: NCT01044342
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule; single oral dose
Study: NCT01044342
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, single oral dose
Study: NCT01044342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, single oral dose
Study: NCT00822003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control tablet
Study: NCT02312206
Drug: NEOD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
Study: NCT04065282
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 bid po D1\~14 Q3W, 3 cycles perioperation
Study: NCT01777594
Drug: G-202
Normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
Study: NCT01910883
Drug: Placebo i.v. solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01512745
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT01975298
Drug: Avonex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon β1A 30 μg/0.5mL administered Intra Muscular
Study: NCT01070823
Drug: Tysabri® (natalizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
Study: NCT01434745
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
Study: NCT00672958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching capsules.
Study: NCT00380965
Drug: Cesamet™ (nabilone)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00466674
Drug: reduced intensity conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: reduced intensity conditioning for allogenic transplant
Study: NCT02707523
Drug: Azithromycin 10 mg
Normalized name: azithromycin 10 MG/ML
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02707523
Drug: Azithromycin 20mg
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02707523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03514407
Drug: INCB059872
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
Study: NCT04453501
Drug: favorable outcome
Normalized name: favor tutti frutti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death)
Study: NCT00755417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Study: NCT02669303
Drug: Methylprednisolone group
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
Study: NCT03154840
Drug: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigate the Relative Bioavailability among Different Eutropin Formulations
Study: NCT00813722
Drug: atenolol (beta blocker) and hydrochlorothiazide (diuretic)
Normalized name: amiloride / atenolol / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tid and 12,5 mg tid
Study: NCT00406419
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate tablet was administered orally at a dose 7.5-25 mg
Study: NCT00406419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to ocrelizumab was administered via IV infusion
Study: NCT01206699
Drug: corticoid (altim® 1.5 ml)
Normalized name: Corticool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
Study: NCT01206699
Drug: physiological solution (1.5 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
Study: NCT00308737
Drug: Technosphere® Insulin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation, 15U/30U
Study: NCT00308737
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive antidiabetes treatment at the discretion of their physicians
Study: NCT01913639
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04261179
Drug: Nanocoll
Normalized name: rhenium sulfide, nanocolloidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg microgram(s), timepoint: 30-60 minutes
Study: NCT03959852
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg/kg of Fentanyl IV administered over at least 1 minute
Study: NCT00164710
Drug: lumefantrine-artemether
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00770588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To match Gefitinib
Study: NCT00080990
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00080990
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00630058
Drug: MP-424(H), PEG-IFN-a-2b, RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Study: NCT00728299
Drug: PomWonderful Juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 oz per day each day for 78 weeks
Study: NCT00728299
Drug: Placebo juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 oz per day for 78 weeks
Study: NCT00630058
Drug: MP-424 (L), PEG-IFN-a-2b, RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
Study: NCT00361075
Drug: transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01448954
Drug: ADC3680B oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 28 days
Study: NCT01448954
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 28 days
Study: NCT01729468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 160 mg per day until 34 weeks of gestation
Study: NCT01834586
Drug: Anesthetic Topical Adhesive Synera
Normalized name: Synera Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week
Study: NCT00672282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00134771
Drug: Nutrient enriched infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01390441
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
Study: NCT01079143
Drug: Certican®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
Study: NCT03494465
Drug: MEDICAL GLAUCOMA TREATMENT
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
Study: NCT00272350
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00272350
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01079143
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
Study: NCT05240274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 500mg OD for 3 months to start within 10 days post-renal transplant
Study: NCT03443414
Drug: RPL554 suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dual PDE3/PDE 4 inhibitor
Study: NCT03443414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT03497715
Drug: Ibuprofen Sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test 2
Study: NCT03497715
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test 3
Study: NCT03497715
Drug: Ibuprofen (Nurofen)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference 1
Study: NCT03497715
Drug: Ibuprofen (Wockhardt)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reference 2
Study: NCT00884897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given as 20 IU BID
Study: NCT01602510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01151215
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, bd
Study: NCT01151215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral
Study: NCT02401971
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Ivgtt
Study: NCT02078492
Drug: 10 mg of Ketorolac
Normalized name: ketorolac 10 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 10 mg of Ketorolac for pain control.
Study: NCT02078492
Drug: 15 mg of Ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 15mg of Ketorolac for pain control.
Study: NCT02078492
Drug: 30 mg of Ketorolac
Normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 30mg of Ketorolac for pain control.
Study: NCT00288223
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
Study: NCT04362137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching-image placebo
Study: NCT01779453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 8 weeks
Study: NCT01642433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, 3x daily
Study: NCT01889069
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
Study: NCT01889069
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
Study: NCT04621461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 5 days